• Bladder, kidney, and other urologic cancers

Valstar Generic Name & Formulations

General Description

Valrubicin 40mg/mL; soln for intravesical instillation after dilution; contains 50% polyoxyl castor oil/50% dehydrated alcohol; preservative-free.

Pharmacological Class


How Supplied

Single-use vials—4, 24


Valstar Indications


Intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.

Valstar Dosage and Administration


Drain bladder before instilliation. 800mg given intravesically via urethral catheter once weekly for 6 weeks. Retain drug for 2 hours before voiding, then void.


Not recommended.

Valstar Contraindications


Concurrent UTI. Small bladder capacity (eg, unable to tolerate a 75mL instillation).

Valstar Boxed Warnings

Not Applicable

Valstar Warnings/Precautions


Monitor for disease recurrence or progression with cystoscopy, biopsy, and urine cytology every 3 months; if there is not a complete response of CIS to treatment after 3 months or if CIS recurs, cystectomy must be reconsidered. Severe irritable bladder symptoms. Perforated bladder. Bladder mucosa compromised. Delay administration for at least 2 weeks after transurethral resection and/or fulguration. Maintain adequate hydration. Pregnancy (Cat. C); avoid, both males and females should use effective birth control. Nursing mothers: not recommended.

Valstar Pharmacokinetics

See Literature

Valstar Interactions

Not Applicable

Valstar Adverse Reactions

Adverse Reactions

Bladder symptoms (eg, urinary frequency, dysuria, urinary urgency, spasm, hematuria, pain, incontinence, cystitis, nocturia, local burning, urethral pain, pelvic pain, UTI).

Valstar Clinical Trials

See Literature

Valstar Note

Not Applicable

Valstar Patient Counseling

See Literature